{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:08:44Z","timestamp":1772118524977,"version":"3.50.1"},"reference-count":16,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T00:00:00Z","timestamp":1583193600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81041002"],"award-info":[{"award-number":["81041002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The efficacy and safety of Epstein\u2010Barr virus (EBV)\u2010specific antigen peptide\u2010activated cytotoxic T lymphocytes (CTLs) in the treatment of refractory or recurrent angioimmunoblastic T\u2010cell lymphoma (AITL) was determined in this prospective one\u2010arm clinical study. Seven males and two females were enrolled with a median age of 70\u2009years. The tumor stages were all stage III and IV. All patients had group B symptoms and IPI scores of 3 to 5 points. All patients received chemotherapy before CTLs infusion which the median chemotherapy cycle was three. The diseases states before CTLs included five cases of disease progression (PD), two cases of recurrence (R), and two cases with residual lesions after chemotherapy. Eight patients received HLA\u2010haploidentical EBV\u2010specific CTLs, and one patient chose autologous CTLs. The number of transfused cells was 1.67 to 2.38\u2009\u00d7\u200910\n                    <jats:sup>10<\/jats:sup>\n                    for one course of CTLs therapy. One patient was treated with three courses of CTLs, three patients were treated with two courses of CTLs, and five patients were treated with one course of CTLs. During the infusion, eight patients had fever, one patient had rash, and no graft\u2010vs\u2010host diseases were observed. The EBV\u2010DNA decreased by more than two orders of magnitude in six patients, and the response rate was 66.7%. Two patients of PD status achieved complete remission (CR), one patient of PD status achieved partial remission, two patients with residual lesions after chemotherapy achieved CR, and four patients had no response. The objective remission rate was 55.6%. After the median follow\u2010up of 14.5 months, five patients died, and three patients were completely relieved while one patient was lost during follow\u2010up. The 3\u2010year overall survival was 44.4% and 3\u2010year progression\u2010free survival was 33.3%. EBV\u2010specific antigen peptide\u2010activated CTLs showed positive effect in certain patients with refractory and recurrent AITL with high clinical safety.\n                  <\/jats:p>","DOI":"10.1002\/hon.2726","type":"journal-article","created":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T10:57:10Z","timestamp":1582282630000},"page":"272-276","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The efficacy and safety of Epstein\u2010Barr virus\u2010specific antigen peptide\u2010activated cytotoxic T\u2010cells treatment for refractory or recurrent angioimmunoblastic T\u2010cell lymphoma: A prospective clinical observational study"],"prefix":"10.1002","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4426-5863","authenticated-orcid":false,"given":"Wang","family":"Bingjie","sequence":"first","affiliation":[{"name":"Department of Hematology Peking University First Hospital  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang","family":"Lihong","sequence":"additional","affiliation":[{"name":"Department of Hematology Peking University First Hospital  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi","family":"Yongjin","sequence":"additional","affiliation":[{"name":"Department of Hematology Peking University First Hospital  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liu","family":"Huihui","sequence":"additional","affiliation":[{"name":"Department of Hematology Peking University First Hospital  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ou","family":"Jinping","sequence":"additional","affiliation":[{"name":"Department of Hematology Peking University First Hospital  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cen","family":"Xi'nan","sequence":"additional","affiliation":[{"name":"Department of Hematology Peking University First Hospital  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,3,3]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197802)41:2<578::AID-CNCR2820410226>3.0.CO;2-8"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf033"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04335.x"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.3647"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-105759"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-692541"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv237"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2009-0"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.06.003"},{"key":"e_1_2_8_11_1","first-page":"1279525","article-title":"A rare ease of Angioimmunoblastic T cell lymphoma with Epstein\u2010Barr virus\u2010negative reed\u2010Sternberg\u2010like B\u2010cells Chyous ascites, and Chylothorax","volume":"2017","author":"Illemsen M","year":"2017","journal-title":"Case Rep Hematol"},{"issue":"6","key":"e_1_2_8_12_1","first-page":"1584","article-title":"Investigation of lymphoma patients' EBV infection status","volume":"22","author":"Wang XY","year":"2014","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1300894"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.5304"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-07-863654"},{"issue":"5","key":"e_1_2_8_16_1","first-page":"1094","article-title":"Epstein\u2013Barr virus status and its prognostic value in lymphoma","volume":"3","author":"Wang BJ","year":"2016","journal-title":"Ann Hematol Oncol"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-371971"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2726","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2726","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hon.2726","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2726","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T06:17:14Z","timestamp":1693808234000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,3]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1002\/hon.2726"],"URL":"https:\/\/doi.org\/10.1002\/hon.2726","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1002\/HON.2726\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2726\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2726\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2726\/v2\/decision1","asserted-by":"object"}]},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,3]]},"assertion":[{"value":"2019-12-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}